WO2009028457A1 - 非アルコール性脂肪肝炎治療薬 - Google Patents

非アルコール性脂肪肝炎治療薬 Download PDF

Info

Publication number
WO2009028457A1
WO2009028457A1 PCT/JP2008/065109 JP2008065109W WO2009028457A1 WO 2009028457 A1 WO2009028457 A1 WO 2009028457A1 JP 2008065109 W JP2008065109 W JP 2008065109W WO 2009028457 A1 WO2009028457 A1 WO 2009028457A1
Authority
WO
WIPO (PCT)
Prior art keywords
liver
therapeutic agent
nonalcoholic steatohepatitis
agent
nonalcoholic
Prior art date
Application number
PCT/JP2008/065109
Other languages
English (en)
French (fr)
Inventor
Toshifumi Aoyama
Naoki Tanaka
Original Assignee
Shinshu University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shinshu University filed Critical Shinshu University
Priority to JP2009530109A priority Critical patent/JPWO2009028457A1/ja
Publication of WO2009028457A1 publication Critical patent/WO2009028457A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

　臨床で軽度乃至重度の非アルコール性脂肪肝炎（ＮＡＳＨ）の患者の治療に用いられ、その脂肪肝や肝炎に対する優れた薬効を示し、安全で長期間服用でき、副作用がない非アルコール性脂肪肝炎治療薬、及び非アルコール性脂肪肝（ＮＡＦＬＤ）の患者の肝機能改善薬を供する。 　非アルコール性脂肪肝炎治療薬は、少なくとも９８％の高純度のエイコサペンタエン酸、その塩及びそのエステルから選ばれる少なくとも一種類からなる不飽和脂肪酸類を含むものである。肝組織機能改善薬は、その不飽和脂肪酸類を含有し、脂肪肝及び／又は肝炎である肝組織の機能異常を改善するものである。
PCT/JP2008/065109 2007-08-29 2008-08-25 非アルコール性脂肪肝炎治療薬 WO2009028457A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009530109A JPWO2009028457A1 (ja) 2007-08-29 2008-08-25 非アルコール性脂肪肝炎治療薬

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007222285 2007-08-29
JP2007-222285 2007-08-29

Publications (1)

Publication Number Publication Date
WO2009028457A1 true WO2009028457A1 (ja) 2009-03-05

Family

ID=40387177

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/065109 WO2009028457A1 (ja) 2007-08-29 2008-08-25 非アルコール性脂肪肝炎治療薬

Country Status (2)

Country Link
JP (2) JPWO2009028457A1 (ja)
WO (1) WO2009028457A1 (ja)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011046204A1 (ja) * 2009-10-16 2011-04-21 持田製薬株式会社 非アルコール性脂肪肝炎関連マーカー
WO2011154833A1 (en) * 2010-06-08 2011-12-15 Mahesh Kandula Cysteamine derivatives and their use in the treatment of nash
WO2014057522A1 (en) * 2012-10-12 2014-04-17 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
WO2015053379A1 (en) * 2013-10-07 2015-04-16 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US9050309B2 (en) 2012-01-06 2015-06-09 Omthera Pharmaceuticals, Inc. DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
JP2016510720A (ja) * 2013-03-15 2016-04-11 持田製薬株式会社 非アルコール性脂肪性肝炎治療のための組成物および方法
US9492545B2 (en) 2012-05-07 2016-11-15 Omthera Pharmaceuticals Inc. Compositions of statins and omega-3 fatty acids
JP2018500318A (ja) * 2014-12-15 2018-01-11 ディーエスエム アイピー アセッツ ビー．ブイ． 非アルコール性脂肪性肝疾患の処置
JP2018023312A (ja) * 2016-08-10 2018-02-15 佐々木食品工業株式会社 食品組成物
JP2018534323A (ja) * 2015-11-19 2018-11-22 シニュー・ファーマ・インコーポレイテッドＳｉＮｅｗ Ｐｈａｒｍａ Ｉｎｃ． 脂肪肝の予防または処置用医薬組成物
JP2019518738A (ja) * 2015-11-13 2019-07-04 シンセン ハイタイド バイオファーマシューティカル リミテッド 組成物、ならびにその適用および薬学的調製の方法
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
WO2021193489A1 (ja) * 2020-03-25 2021-09-30 株式会社アイビー 遊離脂肪酸濃度測定方法および遊離脂肪酸濃度測定用試薬チップ
CN114786676A (zh) * 2019-11-26 2022-07-22 田边三菱制药株式会社 人的非酒精性脂肪性肝炎的预防药或治疗药
CN115814086A (zh) * 2022-07-15 2023-03-21 四川大学华西医院 circPI4KB在诊断和治疗非酒精性脂肪性肝病以及相关药物筛选中的应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7029139B2 (ja) 2018-08-23 2022-03-03 デンカ株式会社 非アルコール性脂肪性肝炎の検出を補助する方法
WO2021157631A1 (ja) 2020-02-04 2021-08-12 デンカ株式会社 非アルコール性脂肪肝炎の検出を補助する方法

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
ACTA HEPATOLOGICA JAPONICA, vol. 4, no. 2, 2005, pages A329,KAN S10-8 *
DIAKOU.MC ET AL.: "Pharmatological treatment of non-alcoholic ateatohepatitis: the current evidence", SCAND. J. GASTROENTEROL., vol. 42, no. 2, February 2007 (2007-02-01), pages 139 - 147 *
FROYLAND L. ET AL.: "Hypotriacylglycerolemic component of fish oil", PROSTAGLANDINS LEUKOT.ESSENT.FATTY ACIDS, vol. 57, no. 4-5, 1997, pages 387 - 388 *
HAJIME ISHII ET AL.: "Hi alcohol-sei kan'en (NASH) model mouse no kanbyohen ni taisuru eicosapentaenoic acid (EPA) no koka", ACTA HEPATOLOGICA JAPONICA, vol. 48, no. 1, 25 April 2007 (2007-04-25), pages A95 O-28 *
HISAKA MINAMI ET AL.: "Fenofibrate,eicosapentaenoic acid ethyl no kan no insulin kanjusei ni taisuru koka", THE JOURNAL OF THE JAPAN DIABETIC SOCIETY, vol. 45, no. 2, 2002, pages S-196,II-G407-22 *
JUN'YA ORIBE ET AL.: "NASH ni taisuru eicosapentaenoic acid (EPA) no koka", ACTA HEPATOLOGICA JAPONICA, vol. 43, no. 2, 2002, pages A397, KAN P-216 *
MASATAKA SEIKE: "Himan tonyobyo gairai ni okeru kanzo senmon'i no yakuwari", MINOPHAGEN MEDICAL REVIEW, vol. 51, no. 4, 2006, pages 258 - 260 *
NAOKI TANAK ET AL.: "Hi alcohol-sei shibo kan'en no hassho kiko to PPAR", JAPANESE SOCIETY OF GASTROENTEROLOGY KAISHI, vol. 99, no. 6, 2002, pages 563 - 569 *
NAOKI TANAKA ET AL.: "Kansaibo no taisha kino shishitsu taisha to seikatsu shukan", KANTASUI, vol. 51, no. 5, 2005, pages 675 - 680 *
NAOKI TANAKA ET AL.: "Kiso kenkyu NASH no hassho shinten inshi PPAR", JAPANESE JOURNAL OF CLINICAL MEDICINE, vol. 64, no. 6, 2006, pages 1089 - 1094 *
PAPATHEODORIDIS GV ET AL.: "Serum apoptotic caspase activity as marker of disease severity in chronic hepatitis C (CH-C) or non-alcoholic fatty liver disease (NAFLD)", JOURNAL OF HEPATOLOGY, vol. 46, no. 1, April 2007 (2007-04-01), pages S282 *
TARANTINO G. ET AL.: "SERUM CONCENTRATIONS OF THE TISSUE POLYPEPTIDE SPECIFIC ANTIGEN IN PATIENTS SUFFERING FROM NON-ALCOHOLIC STEATOHEPATITIS", EUR.J.CLIN.INVEST., vol. 37, no. 1, January 2007 (2007-01-01), pages 48 - 53 *
YASUSHI SAITO ET AL.: "Koshikessho ni taisuru epadel capsules 300 no tsuikazaigata (MND-21S) no rinsho shiyo seiseki", BASIC PHARMACOLOGY&THERAPEUTICS, vol. 26, no. 12, 1998, pages 2047 - 2062 *

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5758298B2 (ja) * 2009-10-16 2015-08-05 持田製薬株式会社 非アルコール性脂肪肝炎関連マーカー
JPWO2011046204A1 (ja) * 2009-10-16 2013-03-07 持田製薬株式会社 非アルコール性脂肪肝炎関連マーカー
US9060981B2 (en) 2009-10-16 2015-06-23 Mochida Pharmaceutical Co., Ltd. Marker associated with non-alcoholic steatohepatitis
WO2011046204A1 (ja) * 2009-10-16 2011-04-21 持田製薬株式会社 非アルコール性脂肪肝炎関連マーカー
WO2011154833A1 (en) * 2010-06-08 2011-12-15 Mahesh Kandula Cysteamine derivatives and their use in the treatment of nash
CN102947287A (zh) * 2010-06-08 2013-02-27 M·坎杜拉 半胱胺衍生物及其在治疗非酒精性脂肪性肝炎中的用途
US10117844B2 (en) 2012-01-06 2018-11-06 Omthera Pharmaceuticals, Inc. DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
US9050309B2 (en) 2012-01-06 2015-06-09 Omthera Pharmaceuticals, Inc. DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
US9050308B2 (en) 2012-01-06 2015-06-09 Omthera Pharmaceuticals, Inc. DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
US9492545B2 (en) 2012-05-07 2016-11-15 Omthera Pharmaceuticals Inc. Compositions of statins and omega-3 fatty acids
WO2014057522A1 (en) * 2012-10-12 2014-04-17 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US10058528B2 (en) 2012-10-12 2018-08-28 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US9486433B2 (en) 2012-10-12 2016-11-08 Mochida Pharmaceuticals Co. Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US9889108B2 (en) 2013-03-15 2018-02-13 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
JP2016510720A (ja) * 2013-03-15 2016-04-11 持田製薬株式会社 非アルコール性脂肪性肝炎治療のための組成物および方法
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
WO2015053379A1 (en) * 2013-10-07 2015-04-16 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
JP2018500318A (ja) * 2014-12-15 2018-01-11 ディーエスエム アイピー アセッツ ビー．ブイ． 非アルコール性脂肪性肝疾患の処置
US10682334B2 (en) 2014-12-15 2020-06-16 Dsm Ip Assets B.V. Treatment for non-alcoholic fatty liver diseases
US11026916B2 (en) 2014-12-15 2021-06-08 Dsm Ip Assets B.V. Treatment for non-alcoholic fatty liver diseases
JP2019518738A (ja) * 2015-11-13 2019-07-04 シンセン ハイタイド バイオファーマシューティカル リミテッド 組成物、ならびにその適用および薬学的調製の方法
JP2022017496A (ja) * 2015-11-13 2022-01-25 シンセン ハイタイド バイオファーマシューティカル リミテッド 組成物、ならびにその適用および薬学的調製の方法
JP7448511B2 (ja) 2015-11-13 2024-03-12 シンセン ハイタイド バイオファーマシューティカル リミテッド 組成物、ならびにその適用および薬学的調製の方法
JP2018534323A (ja) * 2015-11-19 2018-11-22 シニュー・ファーマ・インコーポレイテッドＳｉＮｅｗ Ｐｈａｒｍａ Ｉｎｃ． 脂肪肝の予防または処置用医薬組成物
JP2018023312A (ja) * 2016-08-10 2018-02-15 佐々木食品工業株式会社 食品組成物
CN114786676A (zh) * 2019-11-26 2022-07-22 田边三菱制药株式会社 人的非酒精性脂肪性肝炎的预防药或治疗药
WO2021193489A1 (ja) * 2020-03-25 2021-09-30 株式会社アイビー 遊離脂肪酸濃度測定方法および遊離脂肪酸濃度測定用試薬チップ
CN115814086A (zh) * 2022-07-15 2023-03-21 四川大学华西医院 circPI4KB在诊断和治疗非酒精性脂肪性肝病以及相关药物筛选中的应用
CN115814086B (zh) * 2022-07-15 2024-05-14 四川大学华西医院 circPI4KB在诊断和治疗非酒精性脂肪性肝病以及相关药物筛选中的应用

Also Published As

Publication number Publication date
JPWO2009028457A1 (ja) 2010-12-02
JP2010094131A (ja) 2010-04-30

Similar Documents

Publication Publication Date Title
WO2009028457A1 (ja) 非アルコール性脂肪肝炎治療薬
WO2007030375A3 (en) Lysosomal acid lipase therapy for nafld and related diseases
WO2006014353A3 (en) Glycogen or polysaccharide storage disease treatment method
MY156316A (en) Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products
SG10201903512SA (en) Bile Acid Recycling Inhibitors For Treatment Of Pediatric Cholestatic Liver Diseases
WO2008063300A3 (en) Boronic acids and esters as inhibitors of fatty acid amide hydrolase
WO2006029081A3 (en) Nucleoside-lipid conjugates, their method of preparation and uses thereof
WO2007101005A3 (en) Compositions and methods for effecting controlled posterior vitreous detachment
WO2007002572A3 (en) Nattokinase for reducing whole blood viscosity
WO2008040548A3 (en) Treatment for non-alcoholic-steatohepatitis
EP4306165A3 (en) Compositions, uses and methods for treatment of metabolic disorders and diseases
AR075423A1 (es) Composicion farmaceutica que comprende un inhibidor de sglt-2, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y sus usos
WO2016127019A3 (en) Pharmaceutical compositions for combination therapy
WO2006093348A3 (en) Method and composition for treating peripheral vascular diseases
WO2006130422A3 (en) Endoscope, propulsion system, and method
BRPI0511327A (pt) combinações de glicopirrolato e agonistas do adrenorreceptor beta2
WO2007023154A3 (de) EISEN(III)-KOMPLEXVERBINDtMGEN ZUR BEHANDLUNG VON EISENMANGEL-ZUSTÄNDEN BEI PATIENTEN MIT CHRONISCH-ENTZÜNDLICHER DARMERKRANKUNG
WO2009073050A3 (en) Use of curcumin to block brain tumor formation in vivo
SI1758469T2 (sl) Izboljšanje integritete bariere pri HIV pacientih z uporabo maščobnih kislin
NZ593657A (en) Enema preparations and their use
WO2001017517A3 (en) Use of g(a)-linolenic acid metabolites in the manufacture of a medicament for the treatment or prevention of cancer
HK1143047A1 (en) Cachexia prevention supplement
WO2009004995A1 (ja) 生理活性物質を定着および発現させる方法
EP1166778A3 (en) The use of growth hormone scretagogues to treat systemic lupus erythematosus and inflammatory bowel disease
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08828810

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009530109

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08828810

Country of ref document: EP

Kind code of ref document: A1